On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...